References
1. Sedgh G, Bearak J, Singh S, Bankole A, Popinchalk A, Ganatra B, et al. Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends. The Lancet. 2016;388(10041):258-67.
2. Starrs AM, Ezeh AC, Barker G, Basu A, Bertrand JT, Blum R, et al. Accelerate progress—sexual and reproductive health and rights for all: report of the Guttmacher–Lancet Commission. The Lancet. 2018;391(10140):2642-92.
3. Center for Reproductive Rights. The World’s Abortion Laws 2020 [Available from: https://reproductiverights.org/worldabortionlaws.
4. Chemlal S, Russo G. Why do they take the risk? A systematic review of the qualitative literature on informal sector abortions in settings where abortion is legal. BMC Women’s Health. 2019;19(1):55.
5. Ganatra B, Gerdts C, Rossier C, Johnson BR, Jr., Tunçalp Ö, Assifi A, et al. Global, regional, and subregional classification of abortions by safety, 2010-14: estimates from a Bayesian hierarchical model. The Lancet. 2017;390(10110):2372-81.
6. Fiala C, Danielsson K-G. Review of medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception. 2006;74(1):66-86.
7. Fiala C, Winikoff B, Helström L, Hellborg M, Gemzell-Danielsson K. Acceptability of home-use of misoprostol in medical abortion. Contraception. 2004;70(5):387-92.
8. Gomperts R, Jelinska K, Davies S, Gemzell-Danielsson K, Kleiverda G. Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services. BJOG: An International Journal of Obstetrics & Gynaecology. 2008;115(9):1171-8.
9. Oppegaard KS, Qvigstad E, Fiala C, Heikinheimo O, Benson L, Gemzell-Danielsson K. Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial. The Lancet. 2015;385(9969):698-704.
10. Kopp Kallner H, Fiala C, Stephansson O, Gemzell-Danielsson K. Home self-administration of vaginal misoprostol for medical abortion at 50–63 days compared with gestation of below 50 days. Human Reproduction. 2010;25(5):1153-7.
11. Endler M, Lavelanet A, Cleeve A, Ganatra B, Gomperts R, Gemzell-Danielsson K. Telemedicine for medical abortion: a systematic review. BJOG: An International Journal of Obstetrics & Gynaecology. 2019;126(9):1094-102.
12. Endler M, Cleeve A, Gemzell-Danielsson K. Online access to abortion medications: a review of utilization and clinical outcomes. Best practice & research Clinical obstetrics & gynaecology. 2020;63:74-86.
13. Yang YT, Kozhimannil KB. Medication Abortion Through Telemedicine: Implications of a Ruling by the Iowa Supreme Court. Obstetrics and gynecology. 2016;127(2):313-6.
14. Baiju N, Acharya G, D’Antonio F, Berg R. Effectiveness, safety and acceptability of self-assessment of the outcome of first-trimester medical abortion: a systematic review and meta-analysis. BJOG: An International Journal of Obstetrics & Gynaecology. 2019;126(13):1536-44.
15. Grossman D, Grindlay K. Safety of Medical Abortion Provided Through Telemedicine Compared With In Person. Obstetrics & Gynecology. 2017;130(4).
16. Ngo TD, Park MH, Shakur H, Free C. Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review. Bulletin of the World Health Organization. 2011;89(5):360-70.
17. Moseson H, Herold S, Filippa S, Barr-Walker J, Baum SE, Gerdts C. Self-managed abortion: A systematic scoping review. Best practice & research Clinical obstetrics & gynaecology. 2020;63:87-110.
18. About Women on Web: Women on Web; [Available from: https://www.womenonweb.org/en/page/521/about-women-on-web. .
19. Creinin MD, Chen MJ. Medical abortion reporting of efficacy: the MARE guidelines. Contraception. 2016;94(2):97-103.
20. Standard country or area codes for statistical use (M49): UN Statistics Division; [Available from: https://unstats.un.org/unsd/methodology/m49/.
21. Aiken ARA, Digol I, Trussell J, Gomperts R. Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland. BMJ. 2017;357:j2011.
22. Sjöström S, Dragoman M, Fønhus MS, Ganatra B, Gemzell-Danielsson K. Effectiveness, safety, and acceptability of first-trimester medical termination of pregnancy performed by non-doctor providers: a systematic review. BJOG: An International Journal of Obstetrics & Gynaecology. 2017;124(13):1928-40.
23. Cameron S. Recent advances in improving the effectiveness and reducing the complications of abortion. F1000Research. 2018;7.
24. Singh S, Remez L, Sedgh G, Kwok L, Onda T. Abortion Worldwide 2017: Uneven Progress and Unequal Access. New York: Guttmacher Institute; 2018.
25. Zamberlin N, Romero M, Ramos S. Latin American women’s experiences with medical abortion in settings where abortion is legally restricted. Reproductive Health. 2012;9(1):34.
26. Gomperts R, van der Vleuten K, Jelinska K, da Costa CV, Gemzell-Danielsson K, Kleiverda G. Provision of medical abortion using telemedicine in Brazil. Contraception. 2014;89(2):129-33.
27. Endler M, Beets L, Gemzell Danielsson K, Gomperts R. Safety and acceptability of medical abortion through telemedicine after 9 weeks of gestation: a population-based cohort study. BJOG: An International Journal of Obstetrics & Gynaecology. 2019;126(5):609-18.
28. Gomperts R, Petow SAM, Jelinska K, Steen L, Gemzell-Danielsson K, Kleiverda G. Regional differences in surgical intervention following medical termination of pregnancy provided by telemedicine. Acta Obstetricia et Gynecologica Scandinavica. 2012;91(2):226-31.
29. Fiala C, Cameron S, Bombas T, Parachini M, Agostini A, Lertxundi R, et al. Outcome of first trimester medical termination of pregnancy: definitions and management. The European Journal of Contraception & Reproductive Health Care. 2018;23(6):451-7.